Filing Flows › Supernus Pharmaceuticals (SUPN) › Trokendi XR revenue
Supernus Pharmaceuticals (SUPN) Trokendi XR revenue by quarter
Supernus Pharmaceuticals' Trokendi XR revenue was $10.2M in Q3 2026 (third quarter 2026), +21% from Q2 2026. Over the last 7 quarters it ranged from $8.4M (Q4 2025) to $12.8M (Q1 2025).
| Quarter | Trokendi XR revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $10.2M | +21% | +2% |
| Q2 2026 | $8.4M | -11% | -25% |
| Q1 2026 | $9.5M | +13% | -26% |
| Q4 2025 | $8.4M | -17% | — |
| Q3 2025 | $10.0M | -10% | — |
| Q2 2025 | $11.2M | -13% | — |
| Q1 2025 | $12.8M | — | — |
Q3 2026 at a glance
Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%, net earnings $20.9M, operating cash flow $6.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Supernus Pharmaceuticals' Trokendi XR revenue?
Supernus Pharmaceuticals' Trokendi XR revenue was $10.2M in Q3 2026 (third quarter 2026), +21% from Q2 2026.
How has Supernus Pharmaceuticals' Trokendi XR revenue changed?
Over the last 7 quarters it ranged from $8.4M (Q4 2025) to $12.8M (Q1 2025).
Q3 2026 results → · How Supernus Pharmaceuticals makes money →